Skip to main content

Advertisement

SpringerLink
Log in

Role of comorbidities in spondyloarthritis including psoriatic arthritis

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Spondyloartrhitis (SpA) are a group of diseases characterized by inflammation at articular and entheseal sites. Moreover, patients with SpA suffer from impaired articular function and reduced quality of life. Beyond the articular involvement, SpA and in particular psoriatic arthritis (PsA) are associated with extra-articular manifestations and comorbidities that might increase the burden of the disease. The aim of this article was to review the available evidences on the presence of comorbidities in SpA, including PsA, focusing the attention on the cardiovascular, metabolic aspects, as well as other comorbidities, and their possible management in an integrated manner. Comorbidities in SpA should be carefully evaluated because of their important impact.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377:2127–2137

    Article  PubMed  Google Scholar 

  2. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J et al (2009) The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783

    Article  CAS  PubMed  Google Scholar 

  3. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011) The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31

    Article  CAS  PubMed  Google Scholar 

  4. Lubrano E, De Socio A, Perrotta FM (2017) Unmet needs in axial spondyloarthritis. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-017-8637-0

  5. De Socio A, Perrotta FM, Grasso GM, Lubrano E (2018) Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of Central Italy: results of the CAMPO-RHE study. Postgrad Med 130:137–141

    Article  PubMed  Google Scholar 

  6. Lubrano E, Perrotta FM (2017) The role of IL-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol 13:815–821

    Article  CAS  PubMed  Google Scholar 

  7. Lubrano E, Perrotta FM (2016) Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag 12:1587–1592

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lubrano E, Cantini F, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Marchesoni A (2017) A national survey on the management of psoriatic arthritis using the Delphi method. Clin Exp Rheumatol 35:214–220

    PubMed  Google Scholar 

  9. Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D’Angelo S, Mathieu A et al (2017) Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol 35:991–1010

    PubMed  Google Scholar 

  10. Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 43:350–355

    Article  CAS  PubMed  Google Scholar 

  11. Lubrano E, Perrotta FM, Marchesoni A, D’Angelo S, Ramonda R, Addimanda O et al (2015) Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 42:258–263

    Article  CAS  PubMed  Google Scholar 

  12. Papagoras C, Voulgari PV, Drosos AA (2013) Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 31:612–620

    PubMed  Google Scholar 

  13. Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301

    Article  CAS  PubMed  Google Scholar 

  14. Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70:1921–1925

    Article  PubMed  Google Scholar 

  15. Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima- media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 47:1203–1207

    Article  CAS  Google Scholar 

  16. Perrotta FM, Scarno A, Carboni A, Bernardo V, Montepaone M, Lubrano E, Spadaro A (2013) Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices. Reumatismo 65:105–112

    Article  CAS  PubMed  Google Scholar 

  17. Kang JH, Chen YH, Lin HC (2010) Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 69:1165–1168

    Article  PubMed  Google Scholar 

  18. Ahmed N, Prior JA, Chen Y, Hayward R, Mallen CD, Hider SL (2016) Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol 35:3069–3073

    Article  PubMed  Google Scholar 

  19. Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH (2014) Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. Rheumatol Int 34:265–270

    Article  CAS  PubMed  Google Scholar 

  20. Mathieu S, Gossec L, Dougados M, Soubrier M (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:557–563

    Article  Google Scholar 

  21. Ingegnoli F, Gualtierotti R, Artusi C, Lubrano E (2014) Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk. Expert Rev Clin Immunol 10:307–315

    Article  CAS  PubMed  Google Scholar 

  22. van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE (2012) High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 31:1529–1535

    Article  PubMed  PubMed Central  Google Scholar 

  23. van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, Dijkmans BA, Heymans MW, Lems WF (2012) High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 23:1683–1690

    Article  PubMed  Google Scholar 

  24. Ramírez J, Nieto-González JC, Curbelo Rodríguez R, Castañeda S, Carmona L (2017) Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48:44–52. https://doi.org/10.1016/j.semarthrit.2017.12.001

    Article  PubMed  Google Scholar 

  25. Pray C, Feroz NI, Haroon N (2017) Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int 101:182–192

    Article  CAS  PubMed  Google Scholar 

  26. Mease PJ (2017) Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol 29:304–310

    Article  PubMed  Google Scholar 

  27. Moltó A, Etcheto A, Gossec L, Boudersa N, Claudepierre P, Roux N, Lemeunier L, Martin A, Sparsa L, Coquerelle P, Soubrier M, Perrot S, Dougados M (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77:533–540

    Article  CAS  PubMed  Google Scholar 

  28. Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129–132

    Article  PubMed  Google Scholar 

  29. Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause D, Saracbasi-Zender E, Schmitz-Bortz E, Braun J (2017) Patients with fibromyalgia rarely fulfill classification criteria for axial spondyloarthritis. Rheumatology (Oxford) 57(2017):1541–1547. https://doi.org/10.1093/rheumatology/kex318

    Article  Google Scholar 

  30. Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24–31

    Article  CAS  Google Scholar 

  31. Chan CYY, Tsang HHL, Lau CS, Chung HY (2017) Prevalence of depressive and anxiety disorders and validation of the hospital anxiety and depression scale as a screening tool in axial spondyloarthritis patients. Int J Rheum Dis 20:317–325

    Article  PubMed  Google Scholar 

  32. Meesters JJ, Bremander A, Bergman S, Petersson IF, Turkiewicz A, Englund M (2014) The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 16:418

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U (2012) Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 32:323–330

    Article  CAS  PubMed  Google Scholar 

  34. Cutolo M, Paolino S, Pizzorni C (2014) Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol 32:839–847

    PubMed  Google Scholar 

  35. Chang CC, Chang CW, Nguyen PA, Chang TH, Shih YL, Chang WY et al (2017) Ankylosing spondylitis and the risk of cancer. Oncol Lett 14:1315–1322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Deng C, Li W, Fei Y, Li Y, Zhang F (2016) Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep 6. https://doi.org/10.1038/srep32063

  37. Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F (2016) Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:35–54

    Article  CAS  PubMed  Google Scholar 

  38. van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF et al (2016) Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 75:83–98

    Article  CAS  PubMed  Google Scholar 

  39. Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110

    Article  CAS  PubMed  Google Scholar 

  40. Radner H, Lesperance T, Accortt NA, Solomon DH (2017) Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken) 69:1510–1518

    Article  Google Scholar 

  41. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature. https://doi.org/10.1038/nature05485

  42. Hutcheson J (2015) Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75:272–279. https://doi.org/10.1016/j.cyto.2015.04.004

    Article  CAS  PubMed  Google Scholar 

  43. Chehimi M, Vidal H, Eljaafari A (2017) Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med 6:68

    Article  CAS  PubMed Central  Google Scholar 

  44. Fassio A, Gatti D, Gisondi P, Girolomoni G, Viapiana O, Giollo A (2017) Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo 69:105–110. https://doi.org/10.4081/reumatismo.2017.953

    Article  CAS  PubMed  Google Scholar 

  45. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195–202

    Article  Google Scholar 

  46. Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their cor- relation with disease activity. Ann Rheum Dis 72:1956–1961

    Article  CAS  PubMed  Google Scholar 

  47. Haroon M, Rafiq Chaudhry AB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43:463–464

    Article  CAS  PubMed  Google Scholar 

  48. Eder L, Chandran V, Cook R, Gladman DD (2017) The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol 44:286–291

    Article  PubMed  Google Scholar 

  49. Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ (2014) Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:500–512

    Article  CAS  PubMed  Google Scholar 

  50. Busquets N, Vaquero CG, Moreno JR, Vilaseca DR, Narváez J, Carmona L, Nolla JM (2014) Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Reumatol Clin 10:89–93

    Article  PubMed  Google Scholar 

  51. Gulati AM, Hoff M, Salvesen Ø, Dhainaut A, Semb AG, Kavanaugh A, Haugeberg G (2017) Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag health study 3. RMD Open 3:e000413

    Article  PubMed  PubMed Central  Google Scholar 

  52. Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G, Cauli A et al (2012) Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 39:849–855

    Article  PubMed  Google Scholar 

  53. Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129–132

    Article  PubMed  Google Scholar 

  54. Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H et al (2018) The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford) 57:32–40

    Article  Google Scholar 

  55. Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749–1754

    Article  PubMed  Google Scholar 

  56. McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887–896

    Article  PubMed  Google Scholar 

  57. Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351–360

    Article  PubMed  Google Scholar 

  58. Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, Wu JJ (2017) Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol 31:1999–2009

    Article  CAS  PubMed  Google Scholar 

  59. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB (2006) The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126:2194–2201

    Article  CAS  PubMed  Google Scholar 

  60. Frentz G, Olsen JH (1999) Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140:237–242

    Article  CAS  PubMed  Google Scholar 

  61. Wilton KM, Crowson CS, Matteson EL (2016) Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study. Clin Rheumatol 35:2603–2607

    Article  PubMed  PubMed Central  Google Scholar 

  62. Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G (2015) Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14:706–714

    CAS  PubMed  Google Scholar 

  63. Lubrano E, Perrotta FM (2017) Psoriatic arthritis: is it time to treat-to-target or target to treat? Clin Rheumatol 36:2633–2635

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio”, Università degli Studi del Molise, Via Giovanni Paolo II, C/da Tappino, 86100, Campobasso, Italy

    Silvia Scriffignano, Fabio Massimo Perrotta, Antonia De Socio & Ennio Lubrano

Authors
  1. Silvia Scriffignano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Massimo Perrotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonia De Socio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ennio Lubrano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ennio Lubrano.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scriffignano, S., Perrotta, F.M., De Socio, A. et al. Role of comorbidities in spondyloarthritis including psoriatic arthritis. Clin Rheumatol 38, 3–10 (2019). https://doi.org/10.1007/s10067-018-4332-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4332-7

Keywords

Search

Navigation